Cleveland Clinic Cancer Institute provides complete cancer care enhanced by innovative basic, clinical and translational research. It offers the most effective techniques to achieve long-term survival and improve patients’ quality of life. Cleveland Clinic Cancer Institute’s more than 800 physicians, researchers, nurses and technicians care for thousands of patients each year and provide access to a wide range of clinical trials. Cleveland Clinic Cancer Institute has a global presence, uniting clinicians based in our Cancer Institute, Cleveland Clinic’s other patient-centered institutes, our regional hospitals and health centers, and our operations in Florida, London and Abu Dhabi. Cleveland Clinic is a nonprofit, multi-specialty academic medical center with more than 5,000 staff physicians and researchers who integrate outpatient and hospital care with research and education for better patient outcomes and experience. Cleveland Clinic is a trusted healthcare leader. We’re recognized in the U.S. and throughout the world for our expertise and care.
Be sure to tune into our Cancer Advances podcast where we explore the latest innovative research and clinical advances in the field of oncology. Listen now!
Standards of Care Shift Toward Patient Specificities in Bladder and Prostate Cancers
October 13th 2022Shilpa Gupta, MD, discussed potential therapies for patients with cisplatin-ineligible metastatic urothelial carcinoma, the benefits of sacituzumab govitecan and erdafitinib in later-line urothelial carcinoma, and treatment options for nonmetastatic castration-resistant prostate cancer.
Shepard Discusses Symptoms, Management, and Future Directions in Desmoid Tumors
September 29th 2022Dr Shepard discusses the unpredictable course of desmoid tumors, the use of TKIs for these tumors, and findings from 2 trials presented at the 2022 ESMO Congress that may represent new treatment options for patients with desmoid tumors.
Young-Onset Diagnoses Continue to Rise in Pancreatic and Biliary Cancers
Alok A. Khorana, MD, discusses on-the-rise pancreatic and biliary cancer rates in younger patients, plus the rationale of potential future research into the role of the gut microbiome in these patients.
Maintenance Cabozantinib/Avelumab Combo Under Investigation in Metastatic Urothelial Cancer
The addition of cabozantinib to avelumab is under exploration as a maintenance approach in patients with metastatic urothelial cancer following first-line, platinum-based chemotherapy.
Efforts Are Needed to Address the Enigmatic Rise of Young-Onset Gastrointestinal Cancers
June 16th 2022Despite a steady decline in incidence and mortality rates of many cancers among older individuals in the United States and other high-income countries, an alarming rise in young-onset gastrointestinal cancers has simultaneously occurred.
Immunotherapy Could Still Play a Role After Progression in Patients With RCC
Moshe Ornstein, MD, MA, discusses trials exploring second-line immunotherapy in patients who have progressed on immunotherapy, plus key clinical trial data on kidney cancer and other pressing areas of need for research in renal cell carcinoma.
Cleveland Clinic Faculty Speak to Shifting Standards in Hematologic Malignancies
February 10th 2022We had the pleasure of speaking with faculty from an OncLive® Institutional Perspectives in Cancer webinar on hematologic malignancies, hosted in partnership with Cleveland Clinic, to discuss current practice patterns and emerging therapies in chronic myeloid leukemia, chronic lymphocytic leukemia, myelofibrosis, and acute lymphoblastic leukemia.